Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

Sana Biotechnology, Inc., a company focused on changing the possible for patients through engineered cells, announced that it has sold an aggregate of 21,607,878 shares of the company’s common stock through its at-the-market (“ATM”) facility established through TD Securities (USA) LLC for net proceeds of approximately $69M.